Pfizer Ltd. Technical Momentum Shifts to Bearish Amid Mixed Indicator Signals

Recent Price Movement and Market Context

Pfizer Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, closed at ₹4,780.95 on 10 Mar 2026, down 1.37% from the previous close of ₹4,847.60. The stock traded within a range of ₹4,700.00 to ₹4,840.00 during the day, remaining well below its 52-week high of ₹5,987.65 but comfortably above the 52-week low of ₹3,742.90. This price action reflects a cautious market sentiment amid broader sector volatility.

Comparatively, Pfizer’s recent returns have outpaced the Sensex over the one-year horizon, delivering a 15.43% gain versus the Sensex’s 4.35%. However, shorter-term returns reveal a more mixed picture: a 1-month gain of 0.43% contrasts with the Sensex’s 7.73% decline, while the year-to-date return of -4.05% still outperforms the Sensex’s -8.98%. Over longer periods, Pfizer’s 3-year return of 28.28% slightly trails the Sensex’s 29.70%, and its 10-year return of 148.77% lags behind the Sensex’s 212.84%, indicating moderate long-term growth relative to the broader market.

Technical Indicators Signal Bearish Momentum

The technical landscape for Pfizer has shifted notably, with the overall trend moving from mildly bearish to bearish. The daily moving averages are firmly bearish, signalling that the stock’s short-term momentum is weakening. This is corroborated by the weekly and monthly Bollinger Bands, both indicating bearish pressure, suggesting that volatility is skewed towards downside risk.

The Moving Average Convergence Divergence (MACD) presents a nuanced picture: the weekly MACD remains mildly bullish, hinting at some short-term positive momentum, but the monthly MACD is mildly bearish, reflecting longer-term caution. The Relative Strength Index (RSI) on both weekly and monthly charts shows no clear signal, indicating that the stock is neither overbought nor oversold, but this neutrality does not negate the prevailing bearish trend suggested by other indicators.

The Know Sure Thing (KST) oscillator aligns with the bearish outlook, showing a weekly bearish signal and a mildly bearish monthly stance. Dow Theory analysis further supports this view, with a weekly mildly bearish trend and no definitive monthly trend, underscoring the uncertainty and potential for further downside.

On-Balance Volume (OBV) indicators on both weekly and monthly timeframes show no clear trend, suggesting that volume is not confirming any strong directional move, which may imply a lack of conviction among traders at current price levels.

Mojo Score and Analyst Ratings

Pfizer’s current Mojo Score stands at 37.0, reflecting a Sell rating, a downgrade from its previous Hold grade as of 29 Dec 2025. This downgrade signals a deterioration in the stock’s technical and fundamental outlook according to MarketsMOJO’s comprehensive evaluation framework. The Market Cap Grade remains low at 3, indicating limited market capitalisation strength relative to peers in the Pharmaceuticals & Biotechnology sector.

This downgrade is consistent with the technical indicators’ bearish signals and suggests that investors should exercise caution. The combination of a declining price trend, weakening momentum, and a lower Mojo Grade points to potential challenges ahead for Pfizer’s stock performance.

Moving Averages and Momentum Analysis

The daily moving averages have turned bearish, with the stock price trading below key averages, signalling a negative short-term trend. This is a critical technical development as moving averages often act as dynamic support and resistance levels. The failure to hold above these averages increases the likelihood of further downside pressure.

The weekly MACD’s mildly bullish stance may offer some short-lived relief, but the monthly MACD’s bearish tone suggests that any rallies could be limited and short-lived. The absence of clear RSI signals indicates that the stock is not yet oversold, leaving room for further declines before a potential technical rebound.

Overall, the technical momentum has shifted decisively towards the downside, with multiple indicators aligning to suggest a bearish outlook in the near to medium term.

Comparative Sector and Market Performance

Within the Pharmaceuticals & Biotechnology sector, Pfizer’s technical deterioration contrasts with some peers that have maintained stronger momentum and higher Mojo Scores. The sector itself has faced headwinds due to regulatory uncertainties and pricing pressures, which have weighed on investor sentiment.

While Pfizer’s one-year return of 15.43% outperforms the Sensex’s 4.35%, its five-year return of 2.57% significantly trails the Sensex’s 52.01%, highlighting challenges in sustaining long-term growth. This mixed performance underscores the importance of closely monitoring technical signals to time entries and exits effectively.

Investor Takeaway and Outlook

Investors in Pfizer Ltd. should approach the stock with caution given the recent technical deterioration. The downgrade to a Sell rating and the bearish signals from moving averages, Bollinger Bands, and KST oscillator suggest that the stock may face further downward pressure in the short to medium term.

While the weekly MACD’s mildly bullish signal and neutral RSI readings indicate some potential for short-term consolidation or minor rallies, these are unlikely to reverse the broader bearish trend without significant fundamental catalysts. The lack of volume confirmation from OBV further emphasises the subdued conviction among market participants.

Long-term investors may find comfort in Pfizer’s historical outperformance over one and ten years, but the current technical setup advises prudence. Monitoring key support levels near ₹4,700 and observing any shifts in momentum indicators will be crucial for timing any re-entry or exit decisions.

In summary, Pfizer Ltd. is navigating a challenging technical environment that warrants careful analysis and risk management for investors seeking exposure to the Pharmaceuticals & Biotechnology sector.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →